General News
Published September 8, 2020
LifeWise will be extending cost share waivers for COVID-19 treatment through December 31, 2020. This means that members will not pay a cost share requiring treatment for COVID-19. FDA-approved diagnostic testing and the related provider visit cost share waivers are extended through October 23, 2020 in compliance with Federal rules. All other treatments and services including hospitalizations will be subject to the usual benefits and cost shares. We will continue to evaluate guidance and the scope of COVID-19 and adjust as needed.
For more information regarding COVID-19 testing and treatment visit our producer FAQ or contact your LifeWise representative.